Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2022 Dec 3;23(23):15272.
doi: 10.3390/ijms232315272.

Nrf2 Pathway in Huntington's Disease (HD): What Is Its Role?

Paolo Tucci  1 , Roberta Lattanzi  2 , Cinzia Severini  3 , Luciano Saso  2
Affiliations
Review

Nrf2 Pathway in Huntington's Disease (HD): What Is Its Role?

Paolo Tucci et al. Int J Mol Sci. .

Abstract

Huntington's disease (HD) is an autosomal dominant neurodegenerative disease that occurs worldwide. Despite some progress in understanding the onset of HD, drugs that block or delay symptoms are still not available. In recent years, many treatments have been proposed; among them, nuclear transcriptional factor-2 (Nrf2) enhancer compounds have been proposed as potential therapeutic agents to treat HD. Nrf2 triggers an endogenous antioxidant pathway activated in different neurodegenerative disorders. Probably, the stimulation of Nrf2 during either the early phase or before HD symptoms' onset, could slow or prevent striatum degeneration. In this review, we present the scientific literature supporting the role of Nrf2 in HD and the potential prophylactic and therapeutic role of this compound.

Keywords: Huntington’s disease; Nrf2; antioxidant; neurodegenerative disease; oxidative stress.

PubMed Disclaimer

Conflict of interest statement

The authors declare no conflict of interest.

Figures

Figure 1
Figure 1
The consequence of the toxic protein mHTT synthesis in the HD (created in BioRender.com).
Figure 2
Figure 2
Keap1–Nrf2 Pathway. The oxidative stress leading to Nrf2 nuclear translocation and antixiodant transcription (created in BioRender.com). ? indicates no demonstrated mechanism in neurodegenerative disorders.
Figure 3
Figure 3
Evidence from substances treatment supporting a role for Nrf2 in HD. This figure reports a summary of results from substances tested in vitro and/or in vivo. The yellow rectangles reported substances active on the Nrf2 pathway in the different models (created in BioRender.com).
See this image and copyright information in PMC

References

    1. Pringsheim T., Wiltshire K., Day L., Dykeman J., Steeves T., Jette N. The Incidence and Prevalence of Huntington’s Disease: A Systematic Review and Meta-Analysis. Mov. Disord. 2012;27:1083–1091. doi: 10.1002/mds.25075. - DOI - PubMed
    1. Fisher E.R., Hayden M.R. Multisource Ascertainment of Huntington Disease in Canada: Prevalence and Population at Risk. Mov. Disord. 2014;29:105–114. doi: 10.1002/mds.25717. - DOI - PubMed
    1. Morrison P.J., Harding-Lester S., Bradley A. Uptake of Huntington Disease Predictive Testing in a Complete Population. Clin. Genet. 2011;80:281–286. doi: 10.1111/j.1399-0004.2010.01538.x. - DOI - PubMed
    1. Evans S.J.W., Douglas I., Rawlins M.D., Wexler N.S., Tabrizi S.J., Smeeth L. Prevalence of Adult Huntington’s Disease in the UK Based on Diagnoses Recorded in General Practice Records. J. Neurol. Neurosurg. Psychiatry. 2013;84:1156–1160. doi: 10.1136/jnnp-2012-304636. - DOI - PMC - PubMed
    1. Bates G.P., Dorsey R., Gusella J.F., Hayden M.R., Kay C., Leavitt B.R., Nance M., Ross C.A., Scahill R.I., Wetzel R., et al. Huntington Disease. Nat. Rev. Dis. Primers. 2015;1:15005. doi: 10.1038/nrdp.2015.5. - DOI - PubMed

MeSH terms

Substances